PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) will present clinical, translational and manufacturing data on its investigational CAR T therapy rese-cel at the American Society of Gene & Cell Therapy 2026 Annual Meeting in Boston from May 11 to May 15, 2026.
The presentations include early clinical and translational data from the lowest-dose cohort of rese-cel without preconditioning in pemphigus vulgaris patients enrolled in the RESET-PV trial, along with initial data from autoimmune patients treated with product manufactured using the Cellares Cell Shuttle platform.
Additional data include manufacturing comparability between healthy donor and patient starting material and single-cell profiling across multiple Phase 1/2 RESET trial cohorts.
A presentation on CAR T therapy without preconditioning in pemphigus vulgaris is scheduled for May 14 during a poster reception, with Jenell Volkov presenting.
A second poster on automated CAR T manufacturing using the Cellares platform will also be presented May 14 by Daniel Nunez.
Manufacturing data comparing product quality between healthy donors and autoimmune patients will be presented May 12 by Sagar Sharma during a session on next-generation cell therapy manufacturing.
Single-cell profiling data across multiple autoimmune disease trials will be presented May 13 by Nunez.
Presentation materials will be posted on Cabaletta Bio’s website following the sessions. More information about the company is available at www.cabalettabio.com.
Rese-cel is an investigational autologous CAR T cell therapy targeting CD19-positive cells and is being evaluated across multiple autoimmune indications in the RESET clinical development program.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.